Back to top
more

Nevro (NVRO)

(Delayed Data from NYSE)

$4.92 USD

4.92
240,529

+0.09 (1.86%)

Updated Oct 14, 2024 04:00 PM ET

After-Market: $4.90 -0.02 (-0.41%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What's in the Cards for Livongo Health's (LVGO) Q2 Earnings?

by Zacks Equity Research

Livongo Health (LVGO) second-quarter results are likely to reflect strength in Livongo platform.

AmerisourceBergen (ABC) to Post Q3 Earnings: What's in Store?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal third-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

Livongo Health (LVGO) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

Livongo Health (LVGO) second-quarter results are likely to reflect growth in core Livongo for Diabetes solution.

Varian (VAR) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Varian's (VAR) solid Oncology platform is expected to have driven fiscal third-quarter performance.

McKesson (MCK) to Post Q1 Earnings: What's in the Offing?

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

Nevro (NVRO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Investor confidence is high on Nevro (NVRO), thanks to solid prospects

Why Is Nevro (NVRO) Up 7.1% Since Last Earnings Report?

by Zacks Equity Research

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Hold on to Nevro (NVRO) Stock Now

by Zacks Equity Research

Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.

Nevro's (NVRO) Senza Omnia SCS System Gets CE Mark Approval

by Zacks Equity Research

Nevro (NVRO) received CE mark approval for the Senza Omnia SCS system, which is likely to boost its international presence.

Nevro (NVRO) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.

Nevro (NVRO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 24.27% and 0.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nevro (NVRO) Looks Good: Stock Adds 6.5% in Session

by Zacks Equity Research

Nevro (NVRO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Why Is Nevro (NVRO) Down 34.3% Since Last Earnings Report?

by Zacks Equity Research

Nevro (NVRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Nevro (NVRO): Strong Industry, Solid Earnings Estimate Revisions

by Zacks Equity Research

Nevro (NVRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Nevro (NVRO) Q4 Loss Narrower Than Expected, Revenues Up Y/Y

by Zacks Equity Research

Nevro (NVRO) sees strong segmental contributions in Q4.

Nevro (NVRO) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Nevro (NVRO) delivered earnings and revenue surprises of 29.03% and 3.20%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

What in Store for Universal Health's (UHS) Q4 Earnings?

by Zacks Equity Research

Universal Health's (UHS) Q4 results are likely to reflect gains from both its Acute Care and Behavioral Health segments.

What's in Store for Patterson Companies' (PDCO) Q3 Earnings?

by Zacks Equity Research

Patterson Companies (PDCO) expects Animal Health sales to have been soft in fiscal Q3.

Why Earnings Season Could Be Great for Nevro (NVRO)

by Zacks Equity Research

Nevro (NVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

What's in Store for Fulgent Genetics (FLGT) Q4 Earnings?

by Zacks Equity Research

Fulgent Genetics' (FLGT) fourth-quarter 2019 earnings are likely to reflect top-line growth and elevated test volumes.

What's in Store for Tenet Healthcare's (THC) Q4 Earnings?

by Zacks Equity Research

Tenet Healthcare's (THC) Q4 results are likely to reflect higher revenues, aided by its Hospital and Other Operations as well as Ambulatory segments, partly offset by lower admissions.

What's in the Cards for EverQuote's (EVER) Q4 Earnings?

by Zacks Equity Research

EverQuote's (EVER) Q4 results are likely to reflect revenue growth and expansion in EBITDA.

MEDNAX (MD) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Mednax's (MD) Q4 results reflect growth in same unit revenues and lower general and administrative expenses.